Seminars in Oncology
Volume 33 , Pages S19-S25 , October 2006

Bevacizumab in Older Patients and Patients With Poorer Performance Status

  • Paulo M. Hoff

      Affiliations

    • Dr Hoff has served as a member of a Roche advisory board.
    • Corresponding Author InformationAddress reprint requests to Paulo M. Hoff, MD, FACP, Centro de Oncologia, Hospital Sírio-Libanês, Rua Dona Adma Jafet, 91, São Paulo, SP Brazil 01308-050.

References 

  1. National Cancer Institute: SEER Cancer Statistics Review, 1975-2002. Table I-18. Available at: http://seer.cancer.gov/csr/1975_2002/results_merged/topic_prevalence.pdf. (accessed July 17, 2006)
  2. Engstrom PF, Benson AB, Cooper HS: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2006, November 15, 2005. Available at: http://www.nccn.org (accessed July 17, 2006)
  3. Engstrom PF, Benson AB, Cooper HS: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Rectal Cancer. Version 2.2006, November 15, 2005. Available at: http://www.nccn.org (accessed July 17, 2006)
  4. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–2067
  5. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003;21:1383–1389
  6. Kohne CH, Grothey A, Bokemeyer C, et al. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol. 2001;12:435–442
  7. Sundararajan V, Grann VR, Neugut A. Population based variation in the use of chemotherapy for colorectal cancer in the elderly. Proc Am Soc Clin Oncol. 1999;18:413a;(abstr 1598)
  8. Mor V, Masterson-Allen S, Goldberg RJ, et al. Relationship between age at diagnosis and treatments received by cancer patients. J Am Geriatr Soc. 1985;33:585–589
  9. Au HJ, Mulder KE, Fields AL. Systematic review of management of colorectal cancer in elderly patients. Clin Colorectal Cancer. 2003;3:165–171
  10. Greenfield S, Blanco DM, Elashoff RM, et al. Patterns of care related to age of breast cancer patients. JAMA. 1987;257:2766–2770
  11. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412–2418
  12. Best L, Simmonds P, Baughan C, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer. Cochrane Database Syst Rev. 2000;2000:CD001545
  13. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. BMJ. 2000;321:531–535
  14. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947
  15. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity: Analysis of a large scale phase III trial. Cancer. 1995;75:11–17
  16. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol. 2004;15:1330–1338
  17. D’Andre S, Sargent DJ, Cha SS, et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: A North Central Cancer Treatment Group study. Clin Colorectal Cancer. 2005;4:325–331
  18. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400
  19. Avastin (bevacizumab) prescribing information. South San Francisco, CA: Genentech; 2006;
  20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  21. Fyfe GA, Hurwitz H, Fehrenbacher L, et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. J Clin Oncol. 2004;22:274;(abstr 3617)
  22. Knight R, Miller L, Pirotta N, et al. First-line irinotecan, fluorouracil, leucovorin especially improves survival in metastatic colorectal cancer patients with favorable prognostic indicators. Proc Am Soc Clin Oncol. 2000;19:255a;(abstr 991)
  23. Pharmacia & Upjohn. Camptosar (irinotecan, CTP-11): First-line therapy of metastatic colorectal cancer. Slide presentation at: FDA Oncologic Drugs Advisory Committee, March 16, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/slides/3592s1e (accessed July 17, 2006)
  24. Pharmacia & Upjohn. Camptosar prescribing information: July 21, 2005. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda (accessed July 17, 2006)
  25. Chico IM: Medical officer summary statement for the Advisory Committee: Irinotecan hydrochloride (Camptosar injection) for colorectal cancer (application for Irinotecan as a component of first-line therapy of patients with metastatic carcinoma of the colon and rectum). October 20, 1999. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3592b1d.pdf (accessed July 17, 2006)
  26. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol. 2005;23:3545–3551
  27. Wang E, Anderson S, Hummer A, et al. Dose intensity and toxicity of CPT-11 in geriatric metastatic colorectal cancer patients. Proc Am Soc Clin Oncol. 2002;21:363a;(abstr 1448)
  28. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol. 2005;23:3697–3705
  29. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–65
  30. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non–small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  31. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  32. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials of bevacizumab with chemotherapy. J Clin Oncol. 2005;23:196s;(abstr 3019)
  33. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30
  34. Chawla A, Kabbinavar F, Holmgren E, et al. Quality of life impact of bevacizumab when combined with irinotecan plus 5-fluorouracil/leucovorin or 5-fluorouracil/leucovorin for metastatic colorectal cancer. J Clin Oncol. 2005;23:262s;(abstr 3564)

PII: S0093-7754(06)00317-4

doi: 10.1053/j.seminoncol.2006.08.006

Seminars in Oncology
Volume 33 , Pages S19-S25 , October 2006

Article Tools

* Image Usage & Resolution